登录

小分子抑制剂研发商Endeavor BioMedicines获得1.325亿美元C轮融资

Endeavor BioMedicines Secures $132.5M Series C

VC News Daily 2024-04-25 18:08 翻译由动脉网AI生成,点击反馈

可切换为仅中文


Endeavor BioMedicines, Inc., a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced the closing of a $132.5 million Series C financing, including the conversion of a $5 million convertible instrument.

Endeavor BioMedicines,Inc.,一家临床阶段生物技术公司,开发有可能为危及生命的疾病患者提供转化性临床益处的药物,宣布关闭1.325亿美元的C系列融资,包括转换500万美元的可转换工具。

The oversubscribed round was led by AyurMaya, an affiliate of Matrix Capital Management, with participation from new investors including Fidelity Management & Research Company, Invus, SymBiosis, Velosity Capital, and Woodline Partners; and strong support from existing investors including funds managed by abrdn Inc.

超额认购由矩阵资本管理公司的附属公司AyurMaya牵头,新投资者包括Fidelity Management&Research Company、Invus、SymBiosis、Velosity Capital和Woodline Partners;以及包括abrdn Inc.管理的基金在内的现有投资者的大力支持。

(formerly Tekla Capital Management LLC), Ally Bridge Group, Avidity Partners, Eckuity Capital, Longitude Capital, Omega Funds, Perceptive Advisors, Piper Heartland Healthcare Capital, Silver Arch Bio, and T. Rowe Price Associates..

(原Tekla Capital Management LLC)、Ally Bridge Group、Avidity Partners、Eckuity Capital、Longitude Capital、Omega Funds、Perceptive Advisors、Piper Heartland Healthcare Capital、Silver Arch Bio和T.Rowe Price Associates。

推荐阅读

小分子抑制剂研发商Endeavor BioMedicines候选药物ENV-101可改善特发性肺纤维化患者的肺功能并逆转肺纤维化的关键指标

businesswire 2024-05-20 00:12

2024年4月全球医疗健康领域投融资月报

动脉网APP 2024-05-11 16:06

Endeavor BioMedicines将在2024年美国胸科学会国际会议上展示ENV-101 2a期临床试验的新数据

businesswire 2024-05-01 18:29

VC News Daily

50篇

最近内容 查看更多

癌症虚拟护理服务提供商OncoveryCare获得450万美元种子轮融资

2024-06-14

工作流程自动化解决方案提供商Indico Data获得1900万美元融资

2024-06-06

生物技术公司Envisagenics完成B轮融资

2024-06-05

相关公司查看更多

Endeavor BioMedicines

小分子抑制剂研发商

立即沟通

产业链接查看更多